论文部分内容阅读
近年来,在西德,制药工业的发展以及大批新的专刊提供了大量新抗菌素及其商业制品。然而具有或多或少新性质的许多商业制品却在临床和实践上开始显示出所谓“抗菌素疲软性”,有些商品由于看不出其医疗价值,因而几乎面临被医师抛弃的危险。某些有效的商品,它们的性质、剂量和副作用都是确实可靠的,而往往又可能在化学治疗的改进和开辟新的应用方面被忽视。在这种情况下以什么作为判断标准呢?
In recent years, a large number of new antibiotics and their commercial products have been supplied in West Germany, the pharmaceutical industry and a large number of new special issues. However, many commercial products, with more or less new properties, have started to show so-called “antibiotic weakness” clinically and practically and some, due to their invisible medical value, are at risk of being left behind by their physicians. Certain valid products, whose nature, dosage, and side effects are truly reliable, are often overlooked in the area of chemotherapeutic improvement and the opening up of new applications. In this case, what is the criterion?